Obesity & liver diseases

Product Name
Preclinical
Phase 1
Phase 2
Phase 3
Status1
Preclinical
Phase 1
Phase 2
Phase 3
Pemvidutide
(ALT-801)

Obesity

55%
Status2
Interim data on 50% of subjects Q1 2023
Pemvidutide
(ALT-801)

NASH

45%
Status2
12-week Phase 1b NAFLD trial data announced Sep 2022
24-week Phase 1b (12-wk extension) trial readout Q4 2022
Preclinical
Phase 1
Phase 2
Phase 3
HepTcell

Chronic HBV

55%
Status2
Phase 2 trial readout H2 2023